Mast cell activation syndrome (MCAS): diagnosis and management

Mast cells are tissue-based immune sentinels that normally release histamine, tryptase, and prostaglandins in response to genuine threats — allergens, parasites, venom, and tissue injury. In MCAS, these cells are activated too easily and by too many stimuli, generating waves of symptoms that can affect the skin, gut, airways, cardiovascular system, and nervous system simultaneously. MCAS sits within the broader category of mast cell activation disorders, which also includes secondary MCAS (driven by IgE-mediated allergy) and the more serious monoclonal proliferative disease — systemic mastocytosis — that must be excluded before the MCAS label is applied (ASCIA; Valent JACI 2019).

A. Core clinical — diagnosis in general practice

Clinical presentation

MCAS presents as recurrent, multisystem, episodic symptoms that often cluster together and have identifiable triggers. The most common features are:

• Skin: flushing (especially face, neck, upper chest), pruritus, urticaria, dermographism (writing on the skin with a fingernail raises a wheal), and angioedema.
• Gastrointestinal: nausea, vomiting, abdominal cramping, diarrhoea, and bloating — sometimes severe and disabling.
• Cardiovascular: palpitations, presyncope, and in severe cases hypotension — raising the question of anaphylaxis.
• Respiratory: wheeze, rhinorrhoea, and nasal congestion.
• Neurological: brain fog, fatigue, anxiety, headache, and concentration difficulties.

The pattern that distinguishes MCAS from functional conditions is the episodic clustering — several systems flaring together around a trigger — and the response to antihistamines.

The diagnostic frameworks

Two frameworks are in active use and the tension between them is clinically important.

Valent / WHO consensus criteria (JACI 2019) — strict; requires all three:

1. Recurrent multisystem symptoms consistent with mast-cell mediator release.
2. Objective biochemical evidence — serum tryptase rises by at least 20% plus 2 ng/mL above stable baseline within 1–4 hours of symptoms, or elevated 24-hour urinary N-methylhistamine, prostaglandin D2 metabolites, or leukotriene E4 measured at eviQ-aligned labs.
3. Symptomatic response to mast-cell-targeted therapy (H1 plus H2 antihistamine plus cromolyn or leukotriene receptor antagonist).

Afrin / broader criteria — accept a diagnosis on clinical grounds and therapeutic response when biochemical confirmation is logistically difficult.

The Australian Society of Clinical Immunology and Allergy (ASCIA) takes a pragmatic approach: exclude systemic mastocytosis first (check baseline tryptase; if persistently above 20 ng/mL, refer to haematology for bone marrow biopsy and KIT D816V mutation testing). Then, for symptomatic patients who do not meet strict Valent biochemical criteria, an empirical structured treatment trial is reasonable, with the diagnosis labelled as “probable MCAS” if a meaningful response is achieved.

Investigations

First-line (GP-initiated):

• Baseline serum tryptase — if persistently above 20 ng/mL, refer haematology urgently; if elevated but below 20, consider hereditary alpha-tryptasemia (TPSAB1 gene duplication, ~5% of the population).
• FBC, UEC, LFT, CRP, ESR — screen for haematological or inflammatory causes.
• TSH — exclude hyperthyroidism.
• Coeliac antibodies (anti-tTG IgA + total IgA) — exclude coeliac disease as a GI confounder.
• Specific IgE or skin-prick testing — identify IgE-mediated allergy as an alternative or co-existing diagnosis.

Specialist-level (allergist or haematologist):

• Serum tryptase during acute episode (patient presents within 1–4 hours of onset) — compared against stable baseline.
• 24-hour urine N-methylhistamine, LTE4, and PGD2 metabolites — collected during a symptomatic period.
• KIT D816V mutation in peripheral blood (high-sensitivity PCR) if mastocytosis suspected.
• Bone marrow biopsy + flow cytometry — only if clonal mast cell disease is suspected (sustained tryptase above 20, skin lesions with Darier sign, hepatosplenomegaly, or unexplained osteoporosis).
• Orthostatic vitals (NASA Lean 10-minute stand) — POTS overlap is common.

B. Trigger management — the highest-leverage intervention

A trigger and symptom diary kept for four to six weeks is the most important diagnostic and management tool in MCAS. It should record every food, drink, medication, environmental exposure, and activity preceding each episode, along with the symptom pattern, severity, and duration.

Common triggers to assess:

• Heat — saunas, hot showers, very hot weather; introduce gradual heat acclimatisation.
• Exercise — warm up gradually; carry EpiPen during exercise if anaphylaxis history.
• Alcohol and fermented foods — red wine, beer, aged cheese, cured meats, sauerkraut, fish sauce, yoghurt, soy sauce; a low-histamine diet trial of four to six weeks with a dietitian is reasonable.
• Medications — NSAIDs (aspirin, ibuprofen, diclofenac), codeine and morphine (direct histamine release), iodinated contrast media, atracurium, and some antibiotics; discuss pre-medication protocols for planned procedures with an allergist.
• Stress and hormonal fluctuations — menstrual cycle, perimenopause.
• Infections — episodes often cluster after viral illness.

Permanent and highly restrictive elimination diets without documented trigger confirmation should be avoided — nutrient deficiency and psychological harm can exceed the benefit.

C. Treatment — the step-wise ladder

Step 1: H1 antihistamine at adequate dose

Non-sedating H1 antihistamines are the foundation. Standard allergy doses are frequently insufficient in MCAS — doses need to be higher:

• Cetirizine 10 mg twice daily to four times daily (reduce dose in renal impairment)
• Fexofenadine 180 mg twice to three times daily
• Levocetirizine 5 mg twice daily

All are PBS general schedule and available over-the-counter. Allow four to six weeks at full dose before concluding insufficient response.

Step 2: Add H2 antihistamine

Famotidine 20–40 mg twice daily adds coverage at H2 receptors in the gut, improving nausea, abdominal cramping, and acid-related symptoms. Available over-the-counter. The combination of H1 plus H2 is consistently more effective than H1 alone.

Step 3: Add leukotriene receptor antagonist

Montelukast 10 mg at night targets the prostaglandin/leukotriene mediator arm of mast-cell activation, which H1 and H2 antihistamines do not cover. It helps wheeze, rhinorrhoea, nasal congestion, and pruritus.

Critical prescribing note: The TGA issued a Boxed Warning in 2020 about neuropsychiatric adverse effects of montelukast, including depression, anxiety, sleep disturbance, suicidal ideation, and aggression. Counsel patients before starting, arrange review at two to four weeks, and cease immediately if any neuropsychiatric symptom emerges.

Montelukast is PBS general schedule.

Step 4: Add cromolyn sodium (oral) for GI-predominant disease

Oral cromolyn sodium (sodium cromoglicate) 200 mg four times daily, 30 minutes before meals stabilises intestinal mast cells and significantly reduces nausea, cramping, and diarrhoea in patients with gastrointestinal-predominant MCAS. It requires PBS Authority when prescribed for systemic mastocytosis; for idiopathic MCAS it may be off-label — initiate with specialist guidance.

Step 5: Sedating antihistamine for sleep disruption and breakthrough symptoms

Diphenhydramine 25–50 mg at night or hydroxyzine 25–50 mg at night — PBS general schedule. Caution regarding driving and cognitive function the following day; document counselling.

Step 6: Omalizumab for refractory disease with chronic spontaneous urticaria overlap

Omalizumab (Xolair) is a monoclonal anti-IgE antibody given subcutaneously 150–300 mg monthly. In Australia it is PBS Authority Required (Written) for chronic spontaneous urticaria lasting more than six months that is refractory to standard antihistamine therapy — many MCAS patients meet this criterion alongside their MCAS phenotype. Specialist allergist or dermatologist initiation is required. Emerging open-label evidence supports benefit in true MCAS beyond urticaria.

Anaphylaxis plan — mandatory when there is any anaphylaxis history

Every patient with a history of anaphylaxis — defined as multi-system hypersensitivity with haemodynamic compromise or airway involvement — requires:

• Adrenaline autoinjector (EpiPen or Anapen) — PBS general schedule with NIPDS Authority for severe allergy or anaphylaxis history.
• Written ASCIA Anaphylaxis Action Plan — updated annually, carried at all times.
• MedicAlert bracelet stating MCAS and adrenaline use.
• Education of household members and workplace in EpiPen technique.
• Pre-medication protocol for anaesthesia, contrast, and dental procedures — H1 plus H2 plus corticosteroid 24 hours before; discuss with treating anaesthetist.

D. Australian operations

MBS: Diagnostic visits for complex MCAS typically warrant Level C (item 36) or Level D (item 44) consultations given multisystem complexity. MCAS qualifies as a chronic condition for the GPCCMP preparation (item 965) and review (item 967), enabling allied health referrals to a dietitian for a low-histamine diet, exercise physiologist for POTS-aware reconditioning, and psychologist for anxiety, trauma-informed care, and CBT via Better Access (items 2715/2717).

PBS: H1 antihistamines (cetirizine, fexofenadine, levocetirizine, loratadine) and famotidine are general schedule or over-the-counter. Montelukast is general schedule. Cromolyn sodium oral is Authority Required for systemic mastocytosis. Omalizumab is Authority Required (Written) for chronic spontaneous urticaria. Adrenaline autoinjectors are general schedule with NIPDS Authority.

Specialist referral pathways: Allergist or clinical immunologist for refractory disease, diagnostic uncertainty, or omalizumab consideration. Haematologist urgently if systemic mastocytosis is suspected (sustained tryptase above 20, skin lesions with Darier sign, hepatosplenomegaly, abnormal blood count). POTS overlap — cardiology or autonomic medicine.

E. Special populations

Long COVID: The MCAS-like phenotype — flushing, urticaria, GI symptoms, palpitations, and brain fog emerging or worsening after COVID-19 infection — is reported in 30–50% of patients with severe Long COVID (Weinstock Cell Mol Life Sci 2021). A structured four to six week trial of H1 plus H2 antihistamine plus montelukast is low-risk, low-cost, and frequently beneficial even when formal MCAS criteria are not met. It does not preclude concurrent investigation for POTS or ME/CFS, which should proceed in parallel.

POTS and hypermobility overlap: A significant proportion of patients with MCAS also have postural tachycardia syndrome and hypermobile Ehlers-Danlos syndrome — the “fragile-three” cluster. Electrolyte and fluid support for POTS, joint protection for hypermobility, and graded reconditioning via a POTS-aware exercise physiologist should all be co-managed. Pacing principles from ME/CFS apply when fatigue is prominent.

Perimenopause: Hormonal fluctuations around the menstrual cycle and perimenopause are common MCAS triggers. Tracking symptoms against cycle phase helps confirm the association; some patients report that menopausal hormone therapy stabilises their MCAS, though evidence is limited.

When to escalate

Activate emergency services (000) immediately for anaphylaxis — defined as multi-system hypersensitivity with haemodynamic compromise (blood pressure drop, presyncope, collapse) or airway involvement (throat tightening, stridor, severe wheeze). Administer IM adrenaline from EpiPen into the lateral thigh.

Refer urgently to haematology when a sustained baseline tryptase exceeds 20 ng/mL, or when skin lesions with Darier sign, hepatosplenomegaly, unexplained lymphadenopathy, osteoporosis, or abnormal blood count are present — these raise concern for systemic mastocytosis, a proliferative mast-cell disease requiring bone marrow biopsy.

Refer routinely to allergist or clinical immunologist for: diagnostic uncertainty, refractory symptoms despite optimised step-wise therapy, consideration of omalizumab, or pre-procedural anaesthetic risk assessment.

What this article is and is not

This article provides clinical educational information about MCAS for patients and clinicians. It is not a substitute for individual assessment and management by a qualified specialist. MCAS is a condition where diagnostic criteria are actively debated and where over-diagnosis in functional somatic syndromes carries real harms — including unnecessary dietary restriction, polypharmacy, and delayed recognition of alternative diagnoses. Patients with a history of anaphylaxis should carry their adrenaline autoinjector at all times and review their ASCIA Action Plan with their GP or allergist annually.

---

Sources cited

• ASCIA — Mast Cell Disorders patient information
• ASCIA Anaphylaxis Action Plan resources
• Therapeutic Guidelines (eTG) — Allergy
• Australian Medicines Handbook (AMH) — H1 antihistamines, montelukast
• TGA — Montelukast neuropsychiatric Boxed Warning 2020
• eviQ — Specialised pathology for mast cell mediators
• Valent P et al. — Consensus criteria for mast cell activation syndrome. J Allergy Clin Immunol 2019
• Afrin LB et al. — Proposed diagnostic expansion for MCAS. Diagnosis 2020
• Akin C et al. — MCAS criteria and clinical phenotypes. Am J Hematol 2021
• Picard M et al. — Expert consensus controversy in MCAS. Allergy 2013
• Weinstock LB et al. — MCAS in Long COVID. Cell Mol Life Sci 2021
• WAO 2023 — Mast Cell Activation Syndrome consensus
• PBS — antihistamine, omalizumab, EpiPen, montelukast listings
• MBS items 965 / 967 — GPCCMP
• MBS items 2715 / 2717 — Mental Health Care Plan
• Mast Cell Disease Society Australia
• Allergy & Anaphylaxis Australia
• HealthDirect — Allergy and anaphylaxis